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Abstract
Therapy resistance is a major roadblock in oncology. Exacerbation of molecular dysfunctions typical of cancer cells
have proven effective in twisting oncogenic mechanisms to lethal conditions, thus offering new therapeutic avenues
for cancer treatment. Here, we demonstrate that selective agonists of Transient Receptor Potential cation channel
subfamily M member 8 (TRPM8), a cation channel characteristic of the prostate epithelium frequently overexpressed in
advanced stage III/IV prostate cancers (PCa), sensitize therapy refractory models of PCa to radio, chemo or hormonal
treatment. Overall, our study demonstrates that pharmacological-induced Ca2+ cytotoxicity is an actionable strategy to
sensitize cancer cells to standard therapies.
Introduction
Prostate cancer (PCa) represents the second most
common type of cancer and the fifth leading cause of
death in men in the industrialized countries1. Defeating
metastatic PCa (mPCa) is considered a primary target to
override tumor lethality2, however, the identification of
novel therapies and the development of more effective
clinical protocols for the treatment of locally advanced/
high-risk tumors would significantly contribute to the
reduction of PCa mortality, since these tumors frequently
progress to the incurable stage of the disease3.
Intracellular calcium overload is one of the most pow-
erful mechanisms of cell death in both normal and
malignant cells4. Although several molecular mechanisms
protect PCa cells by Ca2+ cytotoxicity5–9, different Ca2+
permeable channels result overexpressed in PCa. The
Transient Receptor Potential cation channel subfamily M
member 8 (TRPM8) is particularly interesting in the
setting of PCa. Three times more selective for Ca2+ than
K+ and Na+10,11, TRPM8 expression increases in primary
prostate cancer compared to the benign counterpart12–15,
while it is almost invariably lost in metastatic CRPC
(mCRPC)14. Overexpression of TRPM8 in prostate tumor
cells determines an enrichment of operating channel at
the plasma membrane15, which has been shown to be
functional for generating oncogenic stimuli associated
with increased Ca2+ signaling16–20.
Since Ca2+ signaling can promote tumor cell death or
survival depending by its nature, pharmacologic inter-
ventions directed against specific Ca2+ permeable chan-
nels abnormally expressed in cancer cells21–23 can
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represent a valid alternative to induce tumor cytotoxicity
by containing the side effects at acceptable levels.
Here, by applying a multidisciplinary approach to a
tailored in vitro/ex vivo preclinical platform, we demon-
strate that pharmacological activation of TRPM8 in pri-
mary and hormone naïve metastatic models of PCa
sensitizes prostate cancer cells to standard-of-care clinical
protocols for the treatment of locally advanced PCa, thus
pointing out the relevance of ion channels as therapeutic
targets in oncology.
Results
TRPM8 is highly expressed in stage III/IV prostate cancers
Taking advantage of The Cancer Genome Atlas
(TCGA) repository, we have compared TRPM8 expres-
sion in a panel of normal epithelial tissues and derived
primary tumors (Fig. 1a). Among normal epithelia,
TRPM8 expression in the prostate exceeds the expression
of the channel in all the tissues analyzed (Fig. 1a). With
the exclusion of the liver where the amount declines upon
malignant transformation, TRPM8 mRNA rises in several
types of tumors with groups of bladder, breast, kidney and
lung cancer samples characterized by particularly high
expression of the channel (Fig. 1a). Prostate tumors show
in absolute the highest levels of TRPM8 (Fig. 1a).
To accurately profile TRPM8 expression in normal and
tumor prostate tissue, we have interrogated widely used
RNA-seq24–26 and microarray PCa datasets27,28. All
datasets depict a high level of heterogeneity of TRPM8
expression between tumors, nevertheless, invariably, the
amount of the transcript rises in primary tumor samples
compared to benign prostate tissues, to drastically fall in
castration resistant metastatic PCa (Fig. 1a, b and Sup-
plementary Fig. S1a, b).
Read mapping demonstrates that two TRPM8 mRNA
isoforms (UCSC knownGene table GRCh37/hg19) are
expressed in human prostate specimens, encoding,
respectively, the full-length plasma membrane (PM)
channel (6TM TRPM8) and the endoplasmic reticulum
(ER) associated shorter form of the protein (4TM
TRPM8) (Supplementary Fig. S1c, d). Analysis of 52
paired normal and tumor prostate samples annotated in
the TCGA dataset, formally demonstrates: (i) the
increased expression of TRPM8 in the vast majority (36
out of 52) of primary PCa compared to adjacent benign
prostate tissue (Fig. 1c), and (ii) the prevalent expression
of the full-length 6TM TRPM8 isoform in PCa (Fig. 1d).
Finally, analysis of TRPM8 expression in PCa samples
grouped according to the Gleason score reveals no sig-
nificant correlation between transcript amount and
aggressiveness of primary tumors (Supplementary Fig.
S1e). By contrast, elevated TRPM8 expression associates
with an improved overall survival (OS) of PCa patients
(Supplementary Fig. S1f).
To refine our knowledge about TRPM8 expression in
PCa, histological prostate specimens have been analyzed
by immunohistochemistry. A commercially available PCa
TMA (US Biomax Inc. PR208a) has been stained with the
Alomone antibody ACC-049 (Fig. 1e, Supplementary Fig.
S2a and Supplementary Fig. S3b, c, e). TRPM8 immu-
nohistochemistry specifically marks the epithelial com-
partment of the prostate tissue (Fig. 1e, upper panels),
with cancer cells (HMWCKs negative lumens) more
intensely stained than the adjacent normal epithelium
(HMWCKs positive lumens) (Supplementary Fig. S2b).
TMA semi-quantification through pathologist visual
analysis (score 0=weak, 1=moderate, 2= high, and 3=
very high) confirms the heterogeneity of TRPM8 amount
among tumors, with score 2–3 more frequently associated
with advanced stages of the disease (Fig. 1e and Supple-
mentary Fig. S2c, e).
Lastly, parallel TRPM8 immunostaining in primary
prostate tumors and hormone naïve lymph node metas-
tases collected from the same patient shows comparable
amount of the channel (Fig. 1f and Supplementary Fig.
S2d).
Overall, our findings demonstrate that: (i) full-length
plasma membrane 6TM TRPM8 is the most expressed
isoform of the channel in PCa; (ii) TRPM8 immunos-
taining scores high in a relevant percentage of stage III/IV
PCa; and (iii) hormone naïve local lymph node metastases
express similar levels of TRPM8 compared to paired
primary tumors.
Modeling TRPM8 level heterogeneity to study prostate
cells response to channel gating
In order to establish a preclinical in vitro platform
where studying the impact of TRPM8 targeting on normal
and malignant prostate cells expressing different amount
of the channel, we profiled TRPM8 expression in a panel
of commonly used immortalized and metastatic human
prostate cell lines. Endpoint PCR studies with isoform-
specific sets of primers (Supplementary Fig. S1d) define
6TM TRPM8 as the more common TRPM8 transcript in
both immortalized (RWPE-1 and PWR-1E) and meta-
static PCa cell lines (VCaP, LNCaP, LNCaPFastGrowingClone,
MDA-PCa-2b, C4-2, PC3, DU-145, and NCI-H660), while
the shorter 4TM-coding mRNA variant is detectable only
in the LNCaPFGC cells (Supplementary Fig. S3a, d). Of
note, 6TM TRPM8 is mainly expressed in androgen
sensitive immortalized and metastatic human prostate cell
lines (RWPE-1, VCaP, LNCaP, LNCaPFGC, MDA-PCa-2b,
C4-2) (Supplementary Fig. S3a, d). Western blotting
analysis with two antibodies against TRPM8 confirms the
mRNA expression analyses (Supplementary Fig. S3b, c, e)
and shows an unexpectedly abundant 6TM TRPM8 pro-
tein amount in immortalized (RWPE-1 and PWR-1E)
prostate cells irrespective of the low amount of the
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transcript (Supplementary Fig. S3a, b). In line with these
data, analysis of benign, primitive PCa and mCRPC
samples profiled in the TCGA dataset demonstrates a
significant correlation between TRPM8 expression and
androgen receptor (AR) transcriptional score (Supple-
mentary Fig. S3f, upper panels), with the highest level of
statistical significance observed between TRPM8 mRNA
levels and expression of primary AR targeted genes such
as NKX3.1 and KLK2 (Supplementary Fig. S3f, middle and
lower panels).
As first step in the generation of an in vitro platform
where testing the impact of TRPM8 pharmacology on
first-line clinical protocols adopted for the treatment of
locally advanced/high-risk PCa, immortalized androgen
sensitive RWPE-1 (Supplementary Fig. S4) and hormone
naïve lymph node metastatic LNCaPFGC cell lines have
been genetically engineered to model different levels of
TRPM8 expression. In details, full-length (3.312 bp)
cDNA encoding the 6TM TRPM8 isoform (hereinafter
TRPM8) has been cloned from both immortalized RWPE-
1 and metastatic LNCaPFGC cells, controlled by sequen-
cing, and stably integrated through viral transduction in
the genome of RWPE-1 and LNCaPFGC cells, thus gen-
erating respectively the RWPE-1 M8 and LNCaPFGC
M8 sublines. TRPM8 overexpression leads to 4-to-6 times
more protein, and almost three times more TRPM8
loading at the plasma membrane, in RWPE-1 M8 and
LNCaPFGC M8 cells compared to RWPE-1 and LNCaPFGC
(Fig. 2a, b). Of note, RWPE-1 cells show a greater amount
of TRPM8 at the plasma membrane compared to the
LNCaPFGC cells (Fig. 2b). Furthermore, TRPM8 has been
knocked-out in both RWPE-1 and LNCaPFGC lines
through CRISPR-Cas9 methodology to generate the
TRPM8-null RWPE-1 (RWPE-1 CAS) and LNCaPFGC
(LNCaPFGC CAS) sublines (Fig. 2a, b).
No significant differences in cell morphology (Fig. 2c),
proliferation (Fig. 2d), and survival (Fig. 2e) have been
observed by comparing RWPE-1 and LNCaPFGC cell lines
expressing endogenous, overexpressed or knocked-out
levels of TRPM8.
TRPM8 is a cation channel whose function at the
plasma membrane is primarily associated with intracel-
lular Ca2+ influx. In order to assess TRPM8 activity in the
parental and newly generated RWPE-1 cell lines, we have
measured the changes in intracellular Ca2+ concentra-
tions upon administration of different TRPM8 agonists.
Well-studied TRPM8 activators such as menthol (1 mM)
and icilin (10 μM), or the most potent WS-12 (1 μM)29,30,
failed to trigger significant increase in intracellular cal-
cium levels ([Ca2+]i) in RWPE-1 cells (Fig. 3a). A rapid
increase in [Ca2+]i was instead measured in RWPE-1 M8
cells ([Ca2+]i was 84.9 ± 2.8 nM at basal levels and 307.3 ±
17.2, 402.5 ± 27.4, or 249.0 ± 15.2 nM after menthol, WS-
12 or icilin exposure, respectively; n= 122; p < 0.05
between basal or drug-evoked [Ca2+]i levels) (Fig. 3b).
Drug-evoked [Ca2+]i increase is fully reversible upon
drugs washout (Fig. 3b). To prove that the recorded [Ca2+]i
changes effectively depended on TRPM8 channel activa-
tion, electrophysiological recordings have been performed
in these cells upon menthol application. As reported in
Fig. 3c, in RWPE-1 M8 cells menthol triggered the acti-
vation of robust currents showing an outwardly rectifying
profile characteristic for TRPM8 activity (current den-
sities at +80 mV were 83.5 ± 3.7 pA/pF; n= 4), an effect
fully reversible upon drug washout (Fig. 3c). Phosphor-
ylation of calcium-calmodulin dependent protein kinase
IIα (CAMKIIα) on Threonine 286 demonstrates the
induction of Ca2+ signaling in RWPE-1 M8 following
TRPM8 activation with WS-12 (Fig. 3d).
Excessive Ca2+ influx from the extracellular space and
uncontrolled Ca2+ release from the intracellular storages
are well-established potent inducers of apoptotic cell
death4. To study the biological outcome of TRPM8 acti-
vation in nontumor prostate cells, RWPE-1 cell lines
expressing endogenous, increased (M8), or knocked-out
(CAS) levels of the channel have been treated or not with
the most potent TRPM8 agonist WS-12 and analyzed by
Fluorescence Activated Cell Sorting (FACS) for the
apoptotic marker Annexin-V. Results demonstrate that
12 h of 1 μM WS-12 treatment are sufficient to trigger a
(see figure on previous page)
Fig. 1 TRPM8 expression in human PCa. a TCGA RNA-seq dataset showing TRPM8 expression levels in normal tissues and related primary tumors.
b TCGA, SU2C, and Beltran RNA-seq datasets analysis stating TRPM8 expression levels in benign prostate tissue, primary PCa and castration resistant
metastatic adeno-PCa. Data were analyzed using a two-tailed Wilcoxon–Mann–Whitney test with a significance level set at 5%. c TRPM8 mRNA levels
in 52 matched normal and adjacent PCa samples showing increased expression of TRPM8 in PCa compared to adjacent normal tissue in 36 cases,
reduction in 5 and comparable levels in 11. d Relative amount of PM-associated 6TM (full length) and ER-associated 4TM TRPM8 transcript isoforms in
52 matched normal (N) and primary PCa (PCa) samples, as retrieved in TCGA RNA-seq dataset. e TRPM8 immunostaining score of a commercially
available PCa tissue microarray (TMA). TRPM8 immunostaining was scored as weak (0), moderate (1), high (2), or very high (3) on 5 normal prostate
cores and 171 PCa cores representing 57 different cases (3 cores × tumor). Representative images of scored normal prostate tissue and prostate
adenocarcinoma cores are shown. Results are presented as percentage of tumors scored 0-to-3 respect to tumor stage. Stage I: score 1= 36%; score
2= 36%; score 3= 28%; stage II: score 1= 9%, score 2= 64%, score 3= 27%; stage III: score 1= 8%; score 2= 38%; score 3 54%; stage IV: score 1=
12%, score 2= 25%, score 3= 63%. Scale bars, 100 μm. f TRPM8 immunostaining of matched primary PCa (A, B) and hormone naïve lymph node
metastases (a, b). Scale bars, 100 μm.
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robust apoptotic program in almost 40% of RWPE-1 M8
cells, while cell death rate does not change upon treat-
ment in RWPE-1 cells expressing either endogenous or
knocked-out (CAS) levels of the channel (Fig. 4a and
Supplementary Fig. S5a). Menthol or icilin administration
produces similar responses, even though the percentage
of apoptotic RWPE-1 M8 cells is consistently less com-
pared to WS-12 (Supplementary Fig. S5b). Western
blotting analysis for the apoptotic molecular markers
Caspase-3 and PARP fully confirms the induction of a
potent apoptotic cell death program induced by WS-12 in
RWPE-1 M8 prostate cells (Fig. 4b).
Overall, these data establish that increased amount of
TRPM8 at the plasma membrane of prostate cells can
produce intense intracellular Ca2+ currents and the con-
sequent activation of a programmed cell death program
upon administration of potent TRPM8 agonists.
Ca2+ cytotoxicity improves therapy efficacy in in vitro/
ex vivo models of PCa
Lack of human PCa cell lines derived from primary
tumors is a major issue in the study of molecular
mechanisms governing PCa response to radiotherapy and,
in turn, hinders the development of innovative strategies
to overcome radioresistance31,32.
Genomic rearrangements of chromosome 21 driving
ERG expression are among the most common molecular
alterations in human PCa and characterize approximately
50% of patients24. In particular, 3Mb deletion in the q-
arm of human chromosome 21 determines the fusion
between TMPRSS2 exon 1 and ERG exon 433. By binding
TMPRSS2 promoter, AR induces ERGEx4 transcription in
prostate epithelial cells and, in turn, the expression of a N-
terminal truncated form of ERG (ERGMet40), which pre-
serves transcriptional activity. Even though TMPRSS2-
ERG rearrangement is considered an early event in
human prostate tumorigenesis, several in vitro and in vivo
studies exclude functional roles of ERG in PCa onset but
associate ERG activity to tumor progression by providing
cancer cells with migratory and invasive molecular com-
petences34–36. In a large number of the ERG positive PCa,
impairment of PTEN tumor suppressive functions is
considered the determining event driving the tumorigenic
process34–37.
To model such a scenario, both RWPE-1 and RWPE-1
M8 cell lines have been genetically engineered with a viral
vector allowing the doxycycline inducible expression of
ERGMet40 alone or in combination with shRNAs against
PTEN (PTEN-KD) (Supplementary Fig. S6a). Upon 48 h
of 1 µg/ml doxycycline administration, ERGMet40 (here-
inafter ERG) expression (Supplementary Fig. S6b, c)
drives a significant upregulation of classical ERG target
genes in RWPE-1 cells (Supplementary Fig. S6d). Con-
comitantly, different levels of PTEN downregulation and
AKT activation in RWPE-1 cells are achieved through the
expression of two independent shRNAs (Supplementary
Fig. S6c). From a phenotypic point of view, ERG expres-
sion alone is not sufficient to: (i) confer proliferative
advantages (Supplementary Fig. S6e); (ii) bypass growth
inhibition by cell contact (Supplementary Fig. S6f); or (iii)
support cell growth in soft agar (Supplementary Fig. S6g).
However, as previously reported34, ERG confers migratory
and invasive potential to the RWPE-1 cells (Supplemen-
tary Fig. S6h–j). On the other hand, RWPE-1 cells
experiencing ERG expression in combination with PTEN
downregulation show: (i) proliferative advantages (Sup-
plementary Fig. S6e); (ii) bypass of growth inhibition by
contact (Supplementary Fig. S6f); (iii) growth in soft agar
(Supplementary Fig. S6g); and (iv) marked migratory and
invasive propensity (Supplementary Fig. S6h–j), thus
recapitulating the typical behavior of malignant cells35–38.
Radiation therapy (RT) is the first-line treatment for
~50% of all patients diagnosed with non-metastatic PCa32.
Of these, 15% is affected by high-risk/locally advanced
disease at presentation and has increased risk of tumor
recurrence and dying from PCa3.
Administration of a 10 Gy single dose of photons
induces a vast amount of double strands breaks in the
genome of RWPE-1 cells (Supplementary Fig. S7a).
Nevertheless, 48 h after irradiation FACS and western
blot analyses of both premalignant (ERG) and malignant
(ERG/PTEN-KD) models for the apoptotic markers
Annexin-V, Caspase-3, and PARP show a slight increase
of cell death in the treated samples compared to the
untreated controls (Fig. 5a–d and Supplementary Fig.
S7b).
Of note, regardless the amount of TRPM8, ERG/PTEN-
KD RWPE-1 models result minimally sensitive to WS-12
(see figure on previous page)
Fig. 2 Modeling different levels of TRPM8 in RWPE-1 and LNCaPFGC prostate cell lines. a Western blot analysis and quantification of full-length
6TM TRPM8 amount in RWPE-1 and LNCaPFGC cell lines expressing endogenous (WT), overexpressed (M8) or knocked-out (CAS) levels of the protein.
b Immunofluorescence analysis and quantification of PM-associated full-length 6TM TRPM8 in RWPE-1 and LNCaPFGC cell lines with endogenous
(WT), overexpressed (M8), or knocked-out (CAS) levels of the channel. For quantification of PM TRPM8 positive cells a total of 6000 cells were counted
from different fields. Scale bar, 5 μm. c–e Morphology (c), growth (d), and cell death (e) analyses of RWPE-1 and LNCaPFGC cell lines with endogenous
(WT), overexpressed (M8), or knocked-out (CAS) levels of TRPM8. Error bars, mean ± SD. Experiments were performed in triplicate; data were analyzed
using a two-tailed Student’s t-test. **P ≤ 0.01; ***P ≤ 0.001.
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administration (Fig. 5a–d and Supplementary Fig. S7b),
thus demonstrating a direct role of ERG, besides PTEN/
PI3K deregulation, in the establishment of prosurvival
programs opposing calcium cytotoxicity in prostate cells.
Remarkably, combination of X-ray and WS-12 treat-
ments evokes a rapid and massive apoptotic response in
both ERG and ERG/PTEN-KD RWPE-1 M8 cells
expressing greater amount of TRPM8, while leaving
Fig. 3 (See legend on next page.)
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unaltered ERG and ERG/PTEN-KD RWPE-1 cells char-
acterized by endogenous levels of channel (Fig. 5a-d).
Cell-to-cell and cell-to-matrix interactions have been
proven to support cancer cell survival upon exposure to
different types of cellular stressors39. To address this point,
X-rays, WS-12, and X-rays plus WS-12 efficacy has been
compared in ERG and ERG/PTEN-KD RWPE-1 M8 3D
prostospheres. Even in this setting, combination of X-rays
plus WS-12 confirms a more effective apoptotic activity
than individual X-ray or WS-12 treatments (Fig. 5e, f).
Finally, to further strength our results, we have tested the
different treatments in a patient-derived xenograft (PDX
BM-18) originally established from a hormone naïve bone
metastasis40. TRPM8 immunostaining scores 3 (very high)
in BM-18 (Fig. 6a) and western blotting analysis demon-
strates comparable amounts of full-length TRPM8 protein
between BM-18 and RWPE-1 M8 cells (Fig. 6b). By
adopting a recently developed ex vivo/in vitro culture
system, which supports the survival of normal and tumor
human samples for several days41,42, we have tested the
efficacy of combining X-rays with WS-12 on BM-18 (see
Materials and Methods for details). Accordingly, BM-18
slices have been treated with X-rays (10 Gy), WS-12
(1 μM), X-rays+WS-12 or left untreated to serve as con-
trol, and, 48 h later, harvested and processed for immu-
nostaining analyses and western blotting studies. In line
with our findings, X-rays plusWS-12 treatment provokes a
significant reduction of proliferation combined with the
induction of a potent apoptotic program in BM-18, while
single treatments show minimal effects (Fig. 6c–e).
Local lymph nodes are frequently the first site where
cancer cells seed once spread outside the prostate.
Accordingly, the hormone naïve lymph node metastatic
prostate cell line LNCaPFGC represents a valuable proxy
where studying the effect of TRPM8 activation on the
efficacy of standard adjuvant therapies.
Of note, LNCaP cells are PTEN-null and express ETV1,
an additional member of the oncogenic ETS transcription
factor family that is frequently overexpressed in
TMPRSS2-ERG-negative PCa43–45. Intracellular calcium
concentration ([Ca2+]i) has been measured in LNCaPFGC
cell lines expressing endogenous (LNCaPFGC) or
increased (LNCaPFGC M8) amounts of the channel (Fig. 2)
upon treatment with different TRPM8 agonists (Supple-
mentary Fig. S8a, b). Exposure of both LNCaPFGC and
LNCaPFGC M8 cell lines to menthol (1 mM), WS-12
(1 μM), or icilin (10 μM) fails to prompt any measurable
[Ca2+]i increases in the totality of cells tested (Supple-
mentary Fig. S8a, b). Further emphasizing a flawed
response of both cell lines to TRPM8 activation, western
blot analysis of LNCaPFGC and LNCaPFGC M8 cells trea-
ted for 12 hours with the potent TRPM8 agonist WS-12
shows no signs of CaMKIIα phosphorylation on Threo-
nine 286 (Supplementary Fig. S8c), while FACS analysis
for the apoptotic marker Annexin-V shows comparable
rates of cell death in untreated and WS-12 treated
LNCaPFGC and LNCaPFGC M8 cells (Supplementary Fig.
S8d). However, 48 h treatment with WS-12 induces
CAMKIIα phosphorylation on Thr286 in LNCaPFGC and,
even more, in LNCaPFGC M8 (Fig. 6h), and almost double
the percentage of cell death in LNCaPFGC M8 cells
compared to controls (Fig. 6f–h and Supplementary Fig.
S9).
Then, LNCaPFGC, LNCaPFGC M8, and LNCaPFGC CAS
lines have been used to test the efficacy of docetaxel and
enzalutamide, two of the most relevant drugs for the
treatment of advanced PCa. Forty eight hours treatment
with either docetaxel (5 nM) or enzalutamide (1 μM)
minimally affect cell viability of LNCaPFGC, LNCaPFGC
M8, and LNCaPFGC CAS lines. FACS analysis for
Annexin-V shows slight differences between treated and
untreated samples (Fig. 6f, g and Supplementary Fig. S9a,
c), while western blotting highlights Caspase-3 cleavage
only upon docetaxel treatment (Fig. 6h and Supplemen-
tary Fig. S9b).
Contrariwise, combination of WS-12 with either doc-
etaxel or enzalutamide significantly enhances the rate of
cell death in LNCaPFGC cells compared to single drug
(see figure on previous page)
Fig. 3 TRPM8 channel activity in RWPE-1 prostate cells. a Representative images (upper panels) and traces (lower panels) showing [Ca2+]i
changes under control solution (CTR) or upon perfusion with menthol (1 mM), WS-12 (1 μM), or icilin (10 μM) on RWPE-1 cells. Time of drugs exposure
is indicated by the bar on top of the traces. Quantification of [Ca2+]i peaks measured upon perfusion with TRPM8 activators is reported on the right
panel (n= number of analyzed cells). The inset graph indicates the quantification of the total % of cells responsive to tested drugs. b Representative
images (left panels) and traces (middle panels) showing [Ca2+]i under control solution (CTR), upon perfusion with menthol (1 mM), WS-12 (1 μM), or
icilin (10 μM), or after drugs washout on RWPE-1 M8 cells. Time of drugs exposure is indicated by the bar on top of the traces. Quantification of the
[Ca2+]i peaks measured upon perfusion with TRPM8 activators is reported on the right panel (n= number of analyzed cells). The inset graph indicates
the percentage of cells responsive to the drugs tested. c Left panel, representative traces of currents evoked by a 100 ms voltage ramp ranging from
−100mV to +100 mV applied every 4 s in control solution (CTL), during application of menthol (500 μM) or after drug washout (W). Right panel,
representative time-courses of currents recorded at +80 mV (blue symbols) or −80 mV (red symbols) in single RWPE-1 M8 cells upon exposure to
menthol (500 μM). Time of menthol exposure is indicated by the line on top of the traces. d Western blotting analysis with two independent
antibodies (D21E4 and 22B1) showing CaMKIIα activation (phosphorylation of Thr286) following WS-12 treatment of RWPE-1 M8 cells. Cells treated
with ionomycin were used as positive control for calcium dependent CaMKIIα phosphorylation. Error bars, mean ± SEM. Experiments were performed
in at least three experimental sessions; data were analyzed using a two-tailed Student’s t-test. *P ≤ 0.05.
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Fig. 4 RWPE-1 response to TRPM8 agonist WS-12. a Cell death response by FACS (Annexin-V; Sytox-Green) in RWPE-1 cells expressing
endogenous, increased (M8) or knocked-out (CAS) TRPM8 levels following 12 h WS-12 (1 μM) administration. Quantification is reported as percentage
of total cells (lower panel). b Western blotting analysis showing molecular signature of apoptotic cell death (Caspase-3 and PARP cleavage).
Staurosporine was used as positive control. Error bars, mean ± SD. Experiments were performed in triplicate; data were analyzed using a two-tailed
Student’s t-test. ***P ≤ 0.001.
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treatments (Fig. 6f, g and Supplementary Fig. S9c).
Beyond the expectations, both combinations rise the
percentage of cell death to almost 60% in LNCaPFGC M8
cells expressing greater amount of TRPM8 (Fig. 6f, g).
Western blot analyses confirm the activation of apoptotic
cell death programs upon either WS-12 plus docetaxel or
WS-12 plus enzalutamide treatments in both LNCaPFGC
and LNCaPFGC M8 lines, with LNCaPFGC M8 cells
experiencing the most severe responses (Fig. 6h).
Caspase-3 and PARP status fully confirms the lack of
synergy between WS-12 and chemo/hormone treatments
in LNCaPFGC CAS cells (Supplementary Fig. S9b).
Discussion
Radiation therapy (RT) is a main treatment for patients
diagnosed with non-metastatic PCa32. The 5-year overall
survival milestone is achieved by the vast majority of
patients with low aggressive organ-confined tumors;
however, patients affected by high-risk/locally advanced
PCa at presentation have increased risk of dying from the
disease.
Correlation between ionizing radiation (IR) dose and
biochemical disease control (but not overall survival)
recommends a high-dose approach for the treatment of
locally advanced PCa, which, however, leads to toxicity in
several organs of the pelvis46,47. Parallel to innovative
technologies such as intensity modulated radiation therapy
(IMRT) and image guided radiation therapy (IGRT) that
have substantially reduced the volume of radiation deliv-
ered to both gastro-intestinal (GI) and genito-urinary (GU)
systems48,49, a great effort has been dedicated to the
development of radiosensitizers favoring the DNA damage-
dependent cancer cell killing activity of IR.
Here, we demonstrate that targeted dysregulation of cal-
cium homeostasis in prostate cancer cells can be an
actionable venue to improve the efficacy of standard-of-care
therapies for locally advanced/high-risk tumors (Fig. 7).
In prototypes of primary and metastatic PCa recapitu-
lating high TRPM8 expression, Ca2+ cytotoxicity induced
by potent TRPM8 agonists combined with a sublethal dose
of X-rays generates an overwhelming cellular stress that
overcomes the anti-apoptotic barriers established in cancer
cells by the impairment of PTEN/PI3K/AKT axis. Still, the
metastatic progression of the disease is frequently asso-
ciated with complete loss of PTEN in prostate tumor
cells50, which has been demonstrated to counteract
Ca2+-dependent cell death by favoring the proteasome
degradation of IP3R39. In the PTEN-null hormone naïve
lymph node metastatic prostate cell line LNCaP43, Vanden
Abeele and colleagues describe the IP3R1 as the IP3
receptor preferentially expressed, followed by almost three
times lower levels of IP3R3 and very low, if any, expression
of IP3R251. Dysfunctional IP3Rs make TRPM8 agonists
unable to induce a rapid and massive Ca2+ store depletion
in LNCaP, which is the cornerstone of Ca2+-induced
cytotoxicity. However, different by icilin that induces
extensive desensitization of the channel, TRPM8 activation
through either menthol or WS-12 is followed by moderate
channel adaptation29,52,53. This important aspect regarding
TRPM8 pharmacology allows us to extend the analysis to
longer time points and demonstrate that 48 h of WS-12
treatment doubles the percentage of apoptotic cells in
LNCaPFGC. This result together with the phosphorylation
of CaMKII on threonine 286 suggests that prolonged
pharmacological activation of TRPM8 can trigger cyto-
toxicity, possibly via a smoothly graded increase of [Ca2+]i
in LNCaPFGC cells, which is likely contributed by continual
quantal releases of Ca2+ from the ER54–58.
Overall, these data demonstrate that extracellular and/
or intracellular stimuli leading to minimal increases of
[Ca2+]i can still determine an harmful cellular stress if
prolonged over time. Indeed, 48 h of WS-12 treatment
combined with either docetaxel or enzalutamide rises the
percentage of cell death in LNCaPFGC cells overexpressing
the channel from roughly 20% with single treatments to
almost 60%.
In conclusion, our study together with the recently
published high-resolution molecular structure of
TRPM859,60, the development of TRPM8 agonists with
improved pharmacological characteristics61, and innova-
tive methods to deliver TRPM8 agonists to PCa cells62,
support the design of preclinical in vivo trials for testing
(see figure on previous page)
Fig. 5 Apoptotic response to X-rays, WS-12 or their combination in RWPE-1 based models of premalignant and malignant prostate
lesions. a Diagram of the experimental design. Genetically engineered RWPE-1 cells were treated as indicated (BioRender.com). b Representative
flow cytometry analysis of cell death in ERG+ and ERG+ /PTEN-deficient RWPE-1 M8 cells treated with WS-12 (1 μM, 12 h), X-rays (10 Gy) or the
combination of both. Untreated cells were used as control. c Cell death quantification of RWPE-1 M8 cells treated as described in b is reported as
percentage of total cells. d Western blotting analysis of samples described in b shows CaMKIIα activation (phosphorylation of Thr286) following WS-
12 treatment of RWPE-1 M8 and the classical molecular signature of apoptotic cell death (Caspase-3 and PARP cleavage) in RWPE-1 M8-based
premalignant (ERG-shCTR) and malignant (ERG+ shPTEN) models of human prostatic disease treated with X-rays plus WS-12. e Representative ERG+
and ERG+/PTEN-deficient RWPE-1 M8 3D prostopheres treated with WS-12 (1 μM, 12 h), X-rays (10 Gy) or the combination of both. Untreated
spheroids were used as control. Scale bar, 50 μm. f Western blotting analysis of treated prostopheres described in e showing classical molecular
hallmarks of apoptotic cell death (Caspase-3 and PARP cleavage). Error bars, mean ± SD. Experiments were performed in quadruplicate; data were
analyzed using a two-way ANOVA test. **P ≤ 0.01.
Alaimo et al. Cell Death and Disease         (2020) 11:1039 Page 11 of 17
Official journal of the Cell Death Differentiation Association
Fig. 6 (See legend on next page.)
Alaimo et al. Cell Death and Disease         (2020) 11:1039 Page 12 of 17
Official journal of the Cell Death Differentiation Association
safety63 and efficacy of TRPM8 activation as a novel
strategy for a more effective treatment of locally
advanced/high-risk PCa patients, an oncologic population
with urgent unmet needs.
Materials and methods
Analysis of TRPM8 expression levels using RNA-seq data
Landscape of TRPM8 transcript levels in normal and
primary tumor samples across different tissues was retrieved
from24,64. RPKM levels were computed and intersample
quantile normalization was performed. RNA-seq analysis of
TRPM8 and other genes in prostate cancer samples was
conducted using previously published data24–26. AR signal-
ing scores were retrieved from previous analysis25. AR sig-
naling scores measure the Pearson’s correlation coefficient
of the transcript level of 30 genes against a reference
sample25. Normalized RNA-seq counts for TRPM8 isoforms
were obtained from TCGA Legacy Archive (https://portal.
(see figure on previous page)
Fig. 6 TRPM8 immunoscoring predicts X-rays+WS-12 efficacy. a TRPM8 immunostaining of BM-18 PDX. Scale bars, 100 μm. b Western blotting
analysis shows comparable expression levels of TRPM8 in BM-18 and RWPE-1 M8 cells. c Immunofluorescence images showing co-staining of Ki-67
(green, upper panel) or Cleaved Caspase-3 (green, lower panel) with CK8 (red) and DAPI (blue). d Percentage of Ki-67 positive cells on a total of 30,000
cells in at least five different areas of the sample. Scale bars, 50 μm. eWestern blotting analysis in BM-18 PDX tissues slices upon WS-12 (1 μM, 48 h), X-
rays (10 Gy), or X-ray +WS-12 treatments showing molecular hallmarks of apoptotic cell death (Caspase-3 and PARP cleavage). Error bars, mean ± SD.
Data were analyzed using a two-tailed Student’s t-test. *P ≤ 0.05; **P ≤ 0.01; ***P ≤ 0.001. f Representative flow cytometry analysis of apoptotic cell
death by Annexin-V/Sytox-Green labeling in LNCaPFGC M8 cells treated with WS-12 (1 μM), docetaxel (5 nM), enzalutamide (1 μM), WS-12+ docetaxel,
or WS-12 + enzalutamide for 48 h. Untreated cells were used as control. g Quantification of dying cells in LNCaPFGC expressing endogenous (WT),
increased (M8) or knocked-out (CAS) levels of TRPM8 treated as indicated in f. h Western blotting analysis of the indicated samples showing CaMKIIα
activation (phosphorylation of Thr286) following WS-12 treatment of LNCaPFGC WT and M8 cells and the molecular signature of apoptotic cell death
(Caspase-3 and PARP cleavage) upon treatment with combination of WS-12 with docetaxel or enzalutamide. Error bars, mean ± SD. Experiments were
performed in quadruplicate; data were analyzed using a two-way ANOVA test. **P ≤ 0.01.
Fig. 7 Proposed model for therapy resistance bypass in PCa cells. The scheme shows the lethal synergy between standard-of-care therapies and
Ca2+ cytotoxicity induced by potent TRPM8 agonists in PCa cells expressing increased amounts of the channel (BioRender.com).
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gdc.cancer.gov/legacy-archive). Association of high TRPM8
transcript level with OS (Overall Survival), DFI
(Disease-Free Interval) and PFI (Progression-Free Interval)
in the TCGA PCa dataset was performed using data
reported in ref. 65. TRPM8 transcript level was considered
high when greater or equal than the 75th percentile of
overall TRPM8 distribution across all TCGA patients (N=
497). Analysis was performed using Keplan-Meier estimator
and Likelihood Ratio (LR) test statistics.
Cell lines
The human cell lines were purchased from the ATCC
and cultured according to the manufacturer’s instructions
in a humidified incubator at 37°C and 5% CO2. Cell lines
were tested for specific markers by WB and RT-qPCR and
routinely checked for Mycoplasma (MycoAlert Kit, Lonza).
For 3D cell cultures, RWPE-1 cells were seeded in KSFM
medium supplemented with 5% of MatrigelTM (Corning)
and incubated at 37 °C for 8 days. Prostospheres growth
was imaged using a Leica DFC 450 C microscope.
Real-time quantitative PCR
Total RNA was extracted using Direct-zol™ RNA
MiniPrep kit (Euroclone) and the purified RNA was
reverse-transcribed using iScript™ cDNA synthesis Kit
(Biorad) according to the manufacturer’s instructions.
Each qRT-PCR was performed in triplicate on a CFX96
qPCR Thermal cycler (Biorad) and the results were nor-
malized to GAPDH and TBP mRNA levels. The specific
primers sequences used are provided in Supplementary
Table S3.
Western blot
Cells were lysed with RIPA buffer supplemented with
protease and phosphatase inhibitors. Protein samples were
subjected to SDS-PAGE and transferred to PVDF mem-
branes (HybondTM, Fisher Scientific). The antibodies used
are provided in Supplementary Table S4. Immunoblots
were revealed using the ECL Select WB Detection Reagent
(GE Healthcare) and an Alliance LD2 system (UVITEC).
WB were performed in at least three independent biolo-
gical replicates; representative data are shown.
Irradiation
Six wells plates with 70% confluent cells were irra-
diated with a X-ray beam (single dose of 10 Gy) by using
the Xstrahl RS225 X-ray research irradiator cabinets at
the Trento Institute for Fundamental Physics and
Application (TIFPA) at a dose rate of 1 Gy/min at RT.
Following irradiation, cells were treated as indicated in
the figure and postincubated at 37 °C for 4 h (immu-
nofluorescence microscopy) or 12–48 h (FACS and WB
analysis).
Immunofluorescence
Cells were grown on coverslips, fixed with 4% PFA and
permeabilized in 5% FBS/0.1% Triton X-100. Afterward,
cells were blocked and incubated with primary antibodies
overnight at 4°C (see Supplementary Table S4). After
washing, cells were incubated with Alexa Fluor conjugated
secondary antibodies and counterstained with DAPI. For
the semiquantitative analysis of TRPM8 expression, we
adopted a nonpermeabilizing protocol to detect only its
localization at the plasma membrane. Cells grown on
coverslips were washed with ice-cold 2% BSA in PBS and
incubated with anti-TRPM8 (Alomone Labs, ACC-049)
and anti-E-Cadherin antibodies for 1 h at 4 °C. After
washing, cells were incubated with Alexa Fluor conjugated
secondary antibodies, fixed with 4% PFA and counter-
stained with DAPI. For the quantification of plasma
membrane associated TRPM8 channels, TRPM8 dots from
more than 6000 cells were counted by two independent
researchers. All the images were acquired using a Leica
DM6000 CS confocal microscope. Immunofluorescence
studies were performed in at least three independent bio-
logical replicates; representative data are shown.
FACS analysis
Cells were cultured at about 60% confluence in six-well
dishes and treated and/or irradiated as indicated in the
figure. After 12–48 h, cells were pelleted with the
exhausted medium and washed in 1X Binding Buffer
solution. Cell death and apoptosis rates were determined
with Annexin-V-FITC (BD Biosciences) or Annexin-V-
APC (Life Technologies) and 7-AAD (ThermoFisher Sci)
or SYTOXTM-Green Nucleic Acid stain (Life Technolo-
gies), staining according to manufacturer’s instructions.
For FACS analysis a CantoA flow cytometer (BD Bios-
ciences) was used and data were analyzed with FlowJo
software (Treestar). FACS analyses were performed in at
least three independent biological replicates; representa-
tive data are shown.
Fluorescence calcium imaging
Calcium-imaging experiments were performed as pre-
viously described66. Cells were perfused with the medium
with a microperfusion system in the absence or presence
of menthol, WS-12 or icilin. Fluorescence intensity values
were converted in Ca2+ concentrations assuming a Kd of
224 nM67.
Electrophysiology
Macroscopic currents from RWPE-1 stably over-
expressing TRPM8 cells were recorded at room with an
Axopatch 200B amplifier (Molecular Devices, Union City,
CA), using the whole-cell configuration of the patch-
clamp technique, as previously described61,68.
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Ex vivo/in vitro culture system
Ex vivo model with tissue slices obtained from intact
BM-18 patient-derived xenograft (PDX) maintained in
adult male CB17/SCID mice40, was performed as described
previously41,42. Briefly, for single compound (WS-12,
1 μM), X-rays treatment (10 Gy), combination and
untreated control, tissue slices were placed on a nitro-
cellulose membrane in contact with culture medium,
oxygenated and maintained at 37 °C for 48 h. Tissues were
recovered and subjected to WB analysis or fixed with 4%
PFA and embedded in paraffin. In vivo experiment for PDX
collection and maintenance was performed according to
the directions of the ethical committee for animal studies
of Canton Bern, Switzerland (Protocol number BE12/17).
Immunohistochemistry
Cell lines were grown at confluence in 10 cm Petri dishes,
trypsinized and collected by centrifugation. Pellets were
fixed overnight in 4% PFA at 4 °C, dehydrated with alcohols
and embedded in paraffin. Paraffin blocks of cell pellets and
BM-18 were cut at the microtome to obtain 5-µm thick
sections, which were recovered on glass slides, depar-
affinized, and used for immunohistochemistry. Immuno-
histochemical analysis was performed at the Department of
Histopathology (S. Chiara Hospital, Trento, Italy) using an
automatic immunostainer (BOND-III platform, Leica Bio-
systems). Antigen retrieval was carried out with optimized
BOND reagents (Bond epitope retrieval solution 1, Leica
Biosystems) at pH 6. The following primary antibodies were
used: TRPM8 (Alomone Labs, ACC-049) at 1:300 dilution
and Cytokeratin HMW (34βE12) (PA0134, Leica Biosys-
tems) optimally diluted for use (see also Supplementary
Table S4). BOND compact polymer detection solution
(Leica Biosystems) was used for the detection. High-
resolution images were acquired using an Axio Imager
M2 microscope (Zeiss). A prostate adenocarcinoma tissue
microarray (TMA), containing 58 cases of adenocarcinomas
and 6 normal tissues (192 total cores, triplicate cores per
case), was purchased from US Biomax, Inc. (PR208a, see
Supplementary Table S5). Samples histology and intensity of
TRPM8 immunostaining were reviewed by a trained
pathologist (M.B.) to ensure appropriate assignment of the
following scores: weak (0), moderate (1), high (2), and very
high (3). Deidentified primary and lymph node metastatic
human PCa matched samples (n= 6) were retrieved from
the tissue bank archives of the Surgical Pathology Unit of
the S. Chiara Hospital (Trento, Italy) upon approval of the
Hospital ethical committee (Prot.:1946 I.D.:112786962).
TRPM8 stained histologic slides were reviewed indepen-
dently by two trained pathologists (M.B. and F.G.C).
Statistical analysis
Statistical comparison of TRPM8 transcripts levels
across sample’s classes was performed using a two-tailed
Wilcoxon–Mann–Whitney test with a significance level
set at 5%. Correlation between TRPM8 transcript levels,
transcript levels of NK3X-1 and KLK2 and AR score was
performed using Pearson correlation statistics with a
significance level set at 5%. GraphPad Prism 6 software
(GraphPad Software Inc.) was used for all statistical ana-
lyses applied to the experimental data. Student’s t-test or
one-way ANOVA were used for comparison between two
groups, while two-way ANOVA was used to compare the
magnitude of changes among different conditions in more
than two groups. Data are presented as mean ± SD of at
least three independent experiments. P value < 0.05 was
considered as statistically significant (*P < 0.05; **P < 0.01;
***P < 0.001).
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